Peanut Allergy Market Accelerates with Rising Food Allergy Prevalence, Immunotherapy Innovation, and Expanding Preventive Healthcare Solutions

The Global Peanut Allergy Market is witnessing strong growth as increasing prevalence of food allergies, heightened awareness of anaphylaxis risks, and advancements in allergy therapeutics drive demand for effective peanut allergy management solutions. According to market estimates, the market was valued at approximately USD 6.1 billion in 2023 and is projected to exceed USD 12.4 billion by 2030, growing at a CAGR of around 10.8% during the forecast period. Rising incidence of pediatric and adult peanut allergies, growing healthcare awareness, increasing emergency preparedness, and expanding adoption of immunotherapy solutions are key drivers fueling market growth. Peanut allergy treatments and management solutions—including epinephrine auto-injectors, oral immunotherapy (OIT), biologics, diagnostics, and allergy prevention programs—play a crucial role in reducing severe allergic reactions and improving patient quality of life.

Major growth drivers include advancements in oral desensitization therapies, biologic treatments targeting immune pathways, increasing regulatory approvals, and expanding investments in allergy diagnostics and preventive care. Significant opportunities are emerging through next-generation immunotherapies, microbiome-based treatments, AI-powered allergy diagnostics, personalized medicine, and broader market penetration in developing healthcare systems.

US Market Trends and Investments 
In 2025, the United States remains the largest peanut allergy market due to high food allergy prevalence, strong healthcare infrastructure, and robust investment in allergy therapeutics. Major companies such as Stallergenes Greer, DBV Technologies, Nestlé Health Science (Aimmune Therapeutics), Sanofi, and ALK-Abelló are heavily investing in oral immunotherapies, biologic therapies, allergy prevention technologies, and advanced epinephrine delivery systems. Recent trends include expanded adoption of FDA-approved oral immunotherapy products, continued development of epicutaneous immunotherapy patches, and growing investment in school-based allergy prevention programs. Increased insurance coverage, federal food safety regulations, and public awareness campaigns continue to strengthen U.S. market leadership.

Peanut Allergy Market Segmentation 
Based on treatment segmentation, epinephrine auto-injectors hold the largest market share due to their critical role in emergency anaphylaxis management and widespread use globally. By patient type, pediatric patients represent the dominant segment because peanut allergies are highly prevalent among children and often require long-term management. Hospitals, specialty allergy clinics, and retail pharmacies account for the leading end-user segment due to broad treatment accessibility and emergency preparedness requirements.

Preview the Insights First – Download Your Free Sample Report https://www.maximizemarketresearch.com/request-sample/199509/ 

Peanut Allergy Key Players include:
1. DBV Technologies
2. Sanofi
3. Vedanta Biosciences Inc
4. Alladapt Immunotherapeutics, Inc.
5. InnoUp
6. Cambridge Allergy Ltd.
7. COUR Pharmaceuticals
8. Regeneron Pharmaceuticals Inc.
9. Aimmune Therapeutics
10. Moonlight Therapeutics
11. Prota Therapeutics
12. Intrommune Therapeutics
13. Blue Willow Biologics
14. Aravax Pty Ltd.

Preview the Insights First – Download Your Free Sample Report https://www.maximizemarketresearch.com/request-sample/199509/ 

Competitive Analysis
The global peanut allergy market is highly competitive, with leading players emphasizing immunotherapy innovation, strategic expansion, and advanced patient management:

• Nestlé Health Science (Aimmune Therapeutics) leads through FDA-approved oral immunotherapy products and ongoing allergy desensitization advancements.

• DBV Technologies strengthens market share through epicutaneous immunotherapy patch development and pediatric allergy innovation.

• ALK-Abelló drives growth via advanced allergy immunotherapy portfolios and expanding biologic research.

• Stallergenes Greer focuses on allergy diagnostics, immunotherapy development, and precision treatment solutions.

• Sanofi invests in biologic therapies and immune modulation technologies for severe allergic conditions.

These companies are aggressively investing in biologics, long-term desensitization therapies, patient adherence technologies, digital health integration, and preventive allergy management solutions.Preview the Insights First – Download Your Free Sample Report

Preview the Insights First – Download Your Free Sample Report

Regional Analysis

• United States: Holds the largest global market share due to high allergy prevalence, advanced therapeutic approvals, and strong public awareness.

• United Kingdom: National allergy awareness initiatives and improved diagnostic services support steady market growth.

• Germany: Strong pharmaceutical innovation and advanced healthcare systems drive peanut allergy treatment adoption.

• France: Government healthcare support and increasing food allergy awareness strengthen market penetration.

• Japan: Rising food allergy diagnosis rates and expanding immunotherapy access fuel market demand.

• China: Increasing urbanization, changing dietary patterns, and expanding healthcare access create significant long-term opportunities.

North America remains the dominant regional market, while Asia-Pacific demonstrates strong growth potential as awareness and diagnosis improve.

Conclusion
The Global Peanut Allergy Market is positioned for sustained long-term growth, driven by rising food allergy prevalence, immunotherapy advancements, increasing public awareness, and expanding preventive healthcare solutions. Major opportunities lie in biologic therapies, oral and epicutaneous immunotherapies, AI-powered diagnostics, and emerging market expansion. As healthcare systems increasingly prioritize allergy prevention, emergency preparedness, and personalized care, peanut allergy management will remain a cornerstone of future allergy treatment innovation. Companies investing in immune modulation, therapeutic innovation, and patient-centered care ecosystems are expected to secure the strongest competitive advantages in this rapidly evolving global market.

About Maximize Market Research

Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting firm known for delivering accurate, actionable, and data-driven insights. Our expertise spans diverse industries — including medical devices, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. We provide services such as market-validated forecasts, competitive intelligence, strategic consulting, and industry impact analysis, helping businesses navigate market complexities and achieve sustainable growth.

Contact Maximize Market Research

MAXIMIZE MARKET RESEARCH PVT. LTD.
2nd Floor, Naval IT Park Phase 3,
Pune-Bangalore Highway, Narhe,
Pune, Maharashtra 411041, India.
📞 +91 9607365656
📧 sales@maximizemarketresearch.com